Copyright
©The Author(s) 2015.
World J Hepatol. Aug 18, 2015; 7(17): 2053-2057
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2053
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2053
Figure 1 Proposed algorithm for the management of the hepatocellular carcinoma patients who discontinue permanently Sorafenib, combining the results of studies evaluating reason of Sorafenib discontinuation of Iavarone et al[23] and Reig et al[22].
HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; RCTs: Randomized controlled trials.
- Citation: Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057
- URL: https://www.wjgnet.com/1948-5182/full/v7/i17/2053.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i17.2053